Page last updated: 2024-11-13

3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID56963315
CHEMBL ID3188597
CHEBI ID131152
SCHEMBL ID10157115

Synonyms (47)

Synonym
NCGC00347943-01
3-[[2-pyridin-2-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoic acid
S7581
gtpl7027
gsk-j1
3-{[2-(pyridin-2-yl)-6-(2,3,4,5-tetrahydro-1h-3-benzazepin-3-yl)pyrimidin-4-yl]amino}propanoic acid
CS-3322
HY-15648
smr004701325
MLS006010249
gskj1
bdbm60875
3-((6-(4,5-dihydro-1h-benzo[d]azepin-3(2h)-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid
c22h23n5o2
1373422-53-7
SCHEMBL10157115
gsk j1
3-(6-(4,5-dihydro-1h-benzo[d]azepin-3(2h)-yl)-2-(pyridin-2-yl)pyrimidin-4-ylamino)propanoic acid
n-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3h-3-benzazepin-3-yl)-4-pyrimidinyl]-?-alanine
n-[2-(2-pyridinyl)-6-(1,2,4,5-tetra hydro-3h-3-benzazepin-3-yl)-4-pyrimidinyl]-beta-alanin e
HB1405
AKOS024458240
CHEMBL3188597
EX-A571
gskj1; gsk-j1
CHEBI:131152
gsk-j1, >=98% (hplc)
histone demethylase inhibitor j1
J-007002
EX-A1744
NCGC00347943-09
n-[2-(pyridin-2-yl)-6-(1,2,4,5-tetrahydro-3h-3-benzazepin-3-yl)pyrimidin-4-yl]-beta-alanine
FT-0700180
BCP08262
3-((2-(pyridin-2-yl)-6-(1,2,4,5-tetrahydro-3h-benzo[d]azepin-3-yl)pyrimidin-4-yl)amino)propanoic acid
mfcd22683851
Q27077924
AS-16773
EN300-126471
SB19353
CCG-268518
n-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3h-3-benzazepin-3-yl)-4-pyrimidinyl]-beta-alanine
A920905
n-[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3h-3-benzazepin-3-yl)-4- pyrimidinyl]-beta-alanine
A900433
DTXSID101025614
AC-36042

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organonitrogen heterocyclic compoundAny organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency33.17340.00308.794948.0869AID1347053
EWS/FLI fusion proteinHomo sapiens (human)Potency20.34470.001310.157742.8575AID1259252; AID1259253; AID1259256
polyproteinZika virusPotency33.17340.00308.794948.0869AID1347053
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Lysine-specific demethylase 4EHomo sapiens (human)IC50 (µMol)19.95260.20001.95696.3096AID1249054
Lysine-specific demethylase 6BHomo sapiens (human)IC50 (µMol)11.87390.01601.66726.9000AID1249069; AID1272794; AID1594436; AID1801992
Lysine-specific demethylase 6AHomo sapiens (human)IC50 (µMol)24.56830.20003.90179.0000AID1423425; AID1801991
Lysine-specific demethylase 4AHomo sapiens (human)IC50 (µMol)400.00000.20002.83194.7600AID1423423
Lysine-specific demethylase 5AHomo sapiens (human)IC50 (µMol)23.26100.13002.374710.0000AID1423424; AID1801989; AID1801992
Lysine-specific demethylase 5CHomo sapiens (human)IC50 (µMol)13.62330.16002.68377.9433AID1801989; AID1801992
Lysine-specific demethylase 3BHomo sapiens (human)IC50 (µMol)15.68200.21001.70503.2000AID1801991
Prolyl 4-hydroxylaseParamecium bursaria Chlorella virus 1IC50 (µMol)15.90005.00006.26678.5000AID1543452
Lysine-specific demethylase 2BHomo sapiens (human)IC50 (µMol)15.68200.21003.83678.1000AID1801991
Lysine-specific demethylase 5DHomo sapiens (human)IC50 (µMol)16.93000.16002.43006.9000AID1801992
Lysine-specific demethylase 4CHomo sapiens (human)IC50 (µMol)16.47630.16002.11489.4000AID1801990; AID1801992
Lysine-specific demethylase 5BHomo sapiens (human)IC50 (µMol)14.35860.16002.36776.9000AID1801989; AID1801991; AID1801992
Histone lysine demethylase PHF8Homo sapiens (human)IC50 (µMol)15.68200.21001.36203.2000AID1801991
Lysine-specific demethylase 2AHomo sapiens (human)IC50 (µMol)16.93000.16002.45966.9000AID1801992
Lysine-specific demethylase 3AHomo sapiens (human)IC50 (µMol)19.79010.15852.39307.9433AID1249065; AID1801992
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (76)

Processvia Protein(s)Taxonomy
regulation of gene expressionLysine-specific demethylase 4EHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4EHomo sapiens (human)
inflammatory response to antigenic stimulusLysine-specific demethylase 6BHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 6BHomo sapiens (human)
response to activityLysine-specific demethylase 6BHomo sapiens (human)
hippocampus developmentLysine-specific demethylase 6BHomo sapiens (human)
cell fate commitmentLysine-specific demethylase 6BHomo sapiens (human)
endothelial cell differentiationLysine-specific demethylase 6BHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific demethylase 6BHomo sapiens (human)
mesodermal cell differentiationLysine-specific demethylase 6BHomo sapiens (human)
cardiac muscle cell differentiationLysine-specific demethylase 6BHomo sapiens (human)
response to fungicideLysine-specific demethylase 6BHomo sapiens (human)
cellular response to hydrogen peroxideLysine-specific demethylase 6BHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific demethylase 6BHomo sapiens (human)
heart developmentLysine-specific demethylase 6BHomo sapiens (human)
regulation of gene expressionLysine-specific demethylase 6BHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 6AHomo sapiens (human)
regulation of gene expressionLysine-specific demethylase 6AHomo sapiens (human)
heart developmentLysine-specific demethylase 6AHomo sapiens (human)
negative regulation of autophagyLysine-specific demethylase 4AHomo sapiens (human)
positive regulation of gene expressionLysine-specific demethylase 4AHomo sapiens (human)
negative regulation of gene expressionLysine-specific demethylase 4AHomo sapiens (human)
cardiac muscle hypertrophy in response to stressLysine-specific demethylase 4AHomo sapiens (human)
apoptotic chromosome condensationLysine-specific demethylase 4AHomo sapiens (human)
response to nutrient levelsLysine-specific demethylase 4AHomo sapiens (human)
positive regulation of neuron differentiationLysine-specific demethylase 4AHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific demethylase 4AHomo sapiens (human)
negative regulation of astrocyte differentiationLysine-specific demethylase 4AHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4AHomo sapiens (human)
regulation of gene expressionLysine-specific demethylase 4AHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific demethylase 5AHomo sapiens (human)
circadian regulation of gene expressionLysine-specific demethylase 5AHomo sapiens (human)
positive regulation of DNA-templated transcriptionLysine-specific demethylase 5AHomo sapiens (human)
regulation of DNA-binding transcription factor activityLysine-specific demethylase 5AHomo sapiens (human)
facultative heterochromatin formationLysine-specific demethylase 5AHomo sapiens (human)
regulation of DNA-templated transcriptionLysine-specific demethylase 5AHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 5AHomo sapiens (human)
response to toxic substanceLysine-specific demethylase 5CHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific demethylase 5CHomo sapiens (human)
rhythmic processLysine-specific demethylase 5CHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 5CHomo sapiens (human)
regulation of DNA-templated transcriptionLysine-specific demethylase 5CHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 3BHomo sapiens (human)
cellular oxidant detoxificationLysine-specific demethylase 3BHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific demethylase 3BHomo sapiens (human)
negative regulation of transcription by RNA polymerase IILysine-specific demethylase 2BHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 2BHomo sapiens (human)
spermatogenesisLysine-specific demethylase 2BHomo sapiens (human)
midbrain-hindbrain boundary morphogenesisLysine-specific demethylase 2BHomo sapiens (human)
fourth ventricle developmentLysine-specific demethylase 2BHomo sapiens (human)
lateral ventricle developmentLysine-specific demethylase 2BHomo sapiens (human)
third ventricle developmentLysine-specific demethylase 2BHomo sapiens (human)
initiation of neural tube closureLysine-specific demethylase 2BHomo sapiens (human)
positive regulation of cell growthLysine-specific demethylase 2BHomo sapiens (human)
forebrain developmentLysine-specific demethylase 2BHomo sapiens (human)
midbrain developmentLysine-specific demethylase 2BHomo sapiens (human)
hindbrain developmentLysine-specific demethylase 2BHomo sapiens (human)
negative regulation of neuron apoptotic processLysine-specific demethylase 2BHomo sapiens (human)
embryonic camera-type eye morphogenesisLysine-specific demethylase 2BHomo sapiens (human)
positive regulation of stem cell population maintenanceLysine-specific demethylase 2BHomo sapiens (human)
negative regulation of neural precursor cell proliferationLysine-specific demethylase 2BHomo sapiens (human)
protein demethylationLysine-specific demethylase 2BHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific demethylase 2BHomo sapiens (human)
T cell antigen processing and presentationLysine-specific demethylase 5DHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific demethylase 5DHomo sapiens (human)
regulation of DNA-templated transcriptionLysine-specific demethylase 5DHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 5DHomo sapiens (human)
blastocyst formationLysine-specific demethylase 4CHomo sapiens (human)
positive regulation of cell population proliferationLysine-specific demethylase 4CHomo sapiens (human)
stem cell population maintenanceLysine-specific demethylase 4CHomo sapiens (human)
androgen receptor signaling pathwayLysine-specific demethylase 4CHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific demethylase 4CHomo sapiens (human)
regulation of androgen receptor signaling pathwayLysine-specific demethylase 4CHomo sapiens (human)
regulation of stem cell differentiationLysine-specific demethylase 4CHomo sapiens (human)
regulation of gene expressionLysine-specific demethylase 4CHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 4CHomo sapiens (human)
single fertilizationLysine-specific demethylase 5BHomo sapiens (human)
post-embryonic developmentLysine-specific demethylase 5BHomo sapiens (human)
positive regulation of gene expressionLysine-specific demethylase 5BHomo sapiens (human)
positive regulation of mammary gland epithelial cell proliferationLysine-specific demethylase 5BHomo sapiens (human)
cellular response to fibroblast growth factor stimulusLysine-specific demethylase 5BHomo sapiens (human)
negative regulation of DNA-templated transcriptionLysine-specific demethylase 5BHomo sapiens (human)
rhythmic processLysine-specific demethylase 5BHomo sapiens (human)
branching involved in mammary gland duct morphogenesisLysine-specific demethylase 5BHomo sapiens (human)
mammary duct terminal end bud growthLysine-specific demethylase 5BHomo sapiens (human)
response to fungicideLysine-specific demethylase 5BHomo sapiens (human)
uterus morphogenesisLysine-specific demethylase 5BHomo sapiens (human)
lens fiber cell differentiationLysine-specific demethylase 5BHomo sapiens (human)
cellular response to leukemia inhibitory factorLysine-specific demethylase 5BHomo sapiens (human)
regulation of estradiol secretionLysine-specific demethylase 5BHomo sapiens (human)
regulation of DNA-templated transcriptionLysine-specific demethylase 5BHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 5BHomo sapiens (human)
G1/S transition of mitotic cell cycleHistone lysine demethylase PHF8Homo sapiens (human)
chromatin remodelingHistone lysine demethylase PHF8Homo sapiens (human)
brain developmentHistone lysine demethylase PHF8Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone lysine demethylase PHF8Homo sapiens (human)
positive regulation of transcription by RNA polymerase IHistone lysine demethylase PHF8Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone lysine demethylase PHF8Homo sapiens (human)
negative regulation of rDNA heterochromatin formationHistone lysine demethylase PHF8Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone lysine demethylase PHF8Homo sapiens (human)
protein demethylationHistone lysine demethylase PHF8Homo sapiens (human)
double-strand break repair via nonhomologous end joiningLysine-specific demethylase 2AHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 2AHomo sapiens (human)
negative regulation of transcription by competitive promoter bindingLysine-specific demethylase 2AHomo sapiens (human)
circadian regulation of gene expressionLysine-specific demethylase 2AHomo sapiens (human)
regulation of circadian rhythmLysine-specific demethylase 2AHomo sapiens (human)
protein demethylationLysine-specific demethylase 2AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific demethylase 2AHomo sapiens (human)
chromatin remodelingLysine-specific demethylase 3AHomo sapiens (human)
spermatid nucleus elongationLysine-specific demethylase 3AHomo sapiens (human)
hormone-mediated signaling pathwayLysine-specific demethylase 3AHomo sapiens (human)
androgen receptor signaling pathwayLysine-specific demethylase 3AHomo sapiens (human)
positive regulation of DNA-templated transcriptionLysine-specific demethylase 3AHomo sapiens (human)
positive regulation of transcription by RNA polymerase IILysine-specific demethylase 3AHomo sapiens (human)
formaldehyde biosynthetic processLysine-specific demethylase 3AHomo sapiens (human)
positive regulation of cold-induced thermogenesisLysine-specific demethylase 3AHomo sapiens (human)
cellular response to leukemia inhibitory factorLysine-specific demethylase 3AHomo sapiens (human)
regulation of stem cell population maintenanceLysine-specific demethylase 3AHomo sapiens (human)
regulation of stem cell differentiationLysine-specific demethylase 3AHomo sapiens (human)
regulation of transcription by RNA polymerase IILysine-specific demethylase 3AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
metal ion bindingLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4EHomo sapiens (human)
protein bindingLysine-specific demethylase 6BHomo sapiens (human)
beta-catenin bindingLysine-specific demethylase 6BHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 6BHomo sapiens (human)
metal ion bindingLysine-specific demethylase 6BHomo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activityLysine-specific demethylase 6BHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingLysine-specific demethylase 6BHomo sapiens (human)
chromatin DNA bindingLysine-specific demethylase 6BHomo sapiens (human)
protein bindingLysine-specific demethylase 6AHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 6AHomo sapiens (human)
metal ion bindingLysine-specific demethylase 6AHomo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activityLysine-specific demethylase 6AHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingLysine-specific demethylase 6AHomo sapiens (human)
chromatin DNA bindingLysine-specific demethylase 6AHomo sapiens (human)
protein bindingLysine-specific demethylase 4AHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 4AHomo sapiens (human)
ubiquitin protein ligase bindingLysine-specific demethylase 4AHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 4AHomo sapiens (human)
methylated histone bindingLysine-specific demethylase 4AHomo sapiens (human)
histone H3K36 demethylase activityLysine-specific demethylase 4AHomo sapiens (human)
histone H3K36me2/H3K36me3 demethylase activityLysine-specific demethylase 4AHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4AHomo sapiens (human)
transcription cis-regulatory region bindingLysine-specific demethylase 5AHomo sapiens (human)
DNA bindingLysine-specific demethylase 5AHomo sapiens (human)
transcription coactivator activityLysine-specific demethylase 5AHomo sapiens (human)
enzyme inhibitor activityLysine-specific demethylase 5AHomo sapiens (human)
protein bindingLysine-specific demethylase 5AHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 5AHomo sapiens (human)
chromatin DNA bindingLysine-specific demethylase 5AHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 5AHomo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activityLysine-specific demethylase 5AHomo sapiens (human)
methylated histone bindingLysine-specific demethylase 5AHomo sapiens (human)
histone bindingLysine-specific demethylase 5AHomo sapiens (human)
DNA bindingLysine-specific demethylase 5CHomo sapiens (human)
protein bindingLysine-specific demethylase 5CHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 5CHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 5CHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific demethylase 5CHomo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activityLysine-specific demethylase 5CHomo sapiens (human)
antioxidant activityLysine-specific demethylase 3BHomo sapiens (human)
metal ion bindingLysine-specific demethylase 3BHomo sapiens (human)
histone H3K9me/H3K9me2 demethylase activityLysine-specific demethylase 3BHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 3BHomo sapiens (human)
chromatin DNA bindingLysine-specific demethylase 3BHomo sapiens (human)
transcription coregulator activityLysine-specific demethylase 3BHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingLysine-specific demethylase 2BHomo sapiens (human)
DNA bindingLysine-specific demethylase 2BHomo sapiens (human)
protein bindingLysine-specific demethylase 2BHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 2BHomo sapiens (human)
rRNA bindingLysine-specific demethylase 2BHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 2BHomo sapiens (human)
unmethylated CpG bindingLysine-specific demethylase 2BHomo sapiens (human)
histone H3K36 demethylase activityLysine-specific demethylase 2BHomo sapiens (human)
histone H3K36me/H3K36me2 demethylase activityLysine-specific demethylase 2BHomo sapiens (human)
transcription coregulator activityLysine-specific demethylase 2BHomo sapiens (human)
DNA bindingLysine-specific demethylase 5DHomo sapiens (human)
protein bindingLysine-specific demethylase 5DHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 5DHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific demethylase 5DHomo sapiens (human)
metal ion bindingLysine-specific demethylase 5DHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific demethylase 5DHomo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activityLysine-specific demethylase 5DHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4CHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 4CHomo sapiens (human)
enzyme bindingLysine-specific demethylase 4CHomo sapiens (human)
nuclear receptor coactivator activityLysine-specific demethylase 4CHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 4CHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 4CHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific demethylase 4CHomo sapiens (human)
histone H3K36 demethylase activityLysine-specific demethylase 4CHomo sapiens (human)
H3K9me3 modified histone bindingLysine-specific demethylase 4CHomo sapiens (human)
histone H3K9me2/H3K9me3 demethylase activityLysine-specific demethylase 4CHomo sapiens (human)
nucleic acid bindingLysine-specific demethylase 5BHomo sapiens (human)
DNA bindingLysine-specific demethylase 5BHomo sapiens (human)
transcription corepressor activityLysine-specific demethylase 5BHomo sapiens (human)
protein bindingLysine-specific demethylase 5BHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 5BHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 5BHomo sapiens (human)
histone H3K4 demethylase activityLysine-specific demethylase 5BHomo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activityLysine-specific demethylase 5BHomo sapiens (human)
histone bindingLysine-specific demethylase 5BHomo sapiens (human)
sequence-specific double-stranded DNA bindingLysine-specific demethylase 5BHomo sapiens (human)
chromatin bindingHistone lysine demethylase PHF8Homo sapiens (human)
iron ion bindingHistone lysine demethylase PHF8Homo sapiens (human)
protein bindingHistone lysine demethylase PHF8Homo sapiens (human)
zinc ion bindingHistone lysine demethylase PHF8Homo sapiens (human)
2-oxoglutarate-dependent dioxygenase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone H3K9 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
methylated histone bindingHistone lysine demethylase PHF8Homo sapiens (human)
histone H4K20 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone H3K36 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone H3K27me2/H3K27me3 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone H3K36me/H3K36me2 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
histone H3K9me/H3K9me2 demethylase activityHistone lysine demethylase PHF8Homo sapiens (human)
transcription coregulator activityHistone lysine demethylase PHF8Homo sapiens (human)
protein bindingLysine-specific demethylase 2AHomo sapiens (human)
zinc ion bindingLysine-specific demethylase 2AHomo sapiens (human)
histone demethylase activityLysine-specific demethylase 2AHomo sapiens (human)
unmethylated CpG bindingLysine-specific demethylase 2AHomo sapiens (human)
histone H3K36 demethylase activityLysine-specific demethylase 2AHomo sapiens (human)
histone H3K36me/H3K36me2 demethylase activityLysine-specific demethylase 2AHomo sapiens (human)
transcription coregulator activityLysine-specific demethylase 2AHomo sapiens (human)
iron ion bindingLysine-specific demethylase 3AHomo sapiens (human)
protein bindingLysine-specific demethylase 3AHomo sapiens (human)
histone H3K9 demethylase activityLysine-specific demethylase 3AHomo sapiens (human)
nuclear androgen receptor bindingLysine-specific demethylase 3AHomo sapiens (human)
histone H3K9me/H3K9me2 demethylase activityLysine-specific demethylase 3AHomo sapiens (human)
transcription coregulator activityLysine-specific demethylase 3AHomo sapiens (human)
chromatin DNA bindingLysine-specific demethylase 3AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4EHomo sapiens (human)
chromatinLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 4EHomo sapiens (human)
nucleusLysine-specific demethylase 6BHomo sapiens (human)
nucleoplasmLysine-specific demethylase 6BHomo sapiens (human)
MLL3/4 complexLysine-specific demethylase 6BHomo sapiens (human)
nucleusLysine-specific demethylase 6AHomo sapiens (human)
nucleoplasmLysine-specific demethylase 6AHomo sapiens (human)
MLL3/4 complexLysine-specific demethylase 6AHomo sapiens (human)
histone methyltransferase complexLysine-specific demethylase 6AHomo sapiens (human)
fibrillar centerLysine-specific demethylase 4AHomo sapiens (human)
nucleusLysine-specific demethylase 4AHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4AHomo sapiens (human)
cytosolLysine-specific demethylase 4AHomo sapiens (human)
pericentric heterochromatinLysine-specific demethylase 4AHomo sapiens (human)
nucleusLysine-specific demethylase 4AHomo sapiens (human)
chromatinLysine-specific demethylase 4AHomo sapiens (human)
nucleusLysine-specific demethylase 5AHomo sapiens (human)
nucleoplasmLysine-specific demethylase 5AHomo sapiens (human)
nucleolusLysine-specific demethylase 5AHomo sapiens (human)
nucleusLysine-specific demethylase 5AHomo sapiens (human)
chromatinLysine-specific demethylase 5AHomo sapiens (human)
nucleusLysine-specific demethylase 5CHomo sapiens (human)
nucleoplasmLysine-specific demethylase 5CHomo sapiens (human)
cytosolLysine-specific demethylase 5CHomo sapiens (human)
nucleusLysine-specific demethylase 5CHomo sapiens (human)
chromatinLysine-specific demethylase 5CHomo sapiens (human)
nucleoplasmLysine-specific demethylase 3BHomo sapiens (human)
histone deacetylase complexLysine-specific demethylase 3BHomo sapiens (human)
chromatinLysine-specific demethylase 3BHomo sapiens (human)
nucleusLysine-specific demethylase 2BHomo sapiens (human)
nucleoplasmLysine-specific demethylase 2BHomo sapiens (human)
chromosomeLysine-specific demethylase 2BHomo sapiens (human)
nucleolusLysine-specific demethylase 2BHomo sapiens (human)
PcG protein complexLysine-specific demethylase 2BHomo sapiens (human)
fibrillar centerLysine-specific demethylase 5DHomo sapiens (human)
nucleoplasmLysine-specific demethylase 5DHomo sapiens (human)
chromatinLysine-specific demethylase 5DHomo sapiens (human)
nucleusLysine-specific demethylase 5DHomo sapiens (human)
nucleoplasmLysine-specific demethylase 4CHomo sapiens (human)
chromatinLysine-specific demethylase 4CHomo sapiens (human)
pericentric heterochromatinLysine-specific demethylase 4CHomo sapiens (human)
nucleusLysine-specific demethylase 4CHomo sapiens (human)
nucleusLysine-specific demethylase 5BHomo sapiens (human)
nucleoplasmLysine-specific demethylase 5BHomo sapiens (human)
cytosolLysine-specific demethylase 5BHomo sapiens (human)
nucleusLysine-specific demethylase 5BHomo sapiens (human)
chromatinLysine-specific demethylase 5BHomo sapiens (human)
nucleusHistone lysine demethylase PHF8Homo sapiens (human)
nucleoplasmHistone lysine demethylase PHF8Homo sapiens (human)
nucleolusHistone lysine demethylase PHF8Homo sapiens (human)
nuclear membraneHistone lysine demethylase PHF8Homo sapiens (human)
nucleoplasmLysine-specific demethylase 2AHomo sapiens (human)
chromosomeLysine-specific demethylase 2AHomo sapiens (human)
male germ cell nucleusLysine-specific demethylase 3AHomo sapiens (human)
nucleusLysine-specific demethylase 3AHomo sapiens (human)
nucleoplasmLysine-specific demethylase 3AHomo sapiens (human)
cytoplasmLysine-specific demethylase 3AHomo sapiens (human)
membraneLysine-specific demethylase 3AHomo sapiens (human)
histone deacetylase complexLysine-specific demethylase 3AHomo sapiens (human)
chromatinLysine-specific demethylase 3AHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (69)

Assay IDTitleYearJournalArticle
AID1346057Human lysine demethylase 6B (1.14.11.- Histone demethylases)2014Nature, Oct-02, Volume: 514, Issue:7520
Inhibition of demethylases by GSK-J1/J4.
AID1346065Human lysine demethylase 5B (1.14.11.- Histone demethylases)2014Nature, Oct-02, Volume: 514, Issue:7520
Inhibition of demethylases by GSK-J1/J4.
AID1346027Human lysine demethylase 5C (1.14.11.- Histone demethylases)2014Nature, Oct-02, Volume: 514, Issue:7520
Inhibition of demethylases by GSK-J1/J4.
AID1346086Human lysine demethylase 6A (1.14.11.- Histone demethylases)2014Nature, Oct-02, Volume: 514, Issue:7520
Inhibition of demethylases by GSK-J1/J4.
AID1346112Human lysine demethylase 5A (1.14.11.- Histone demethylases)2014Nature, Oct-02, Volume: 514, Issue:7520
Inhibition of demethylases by GSK-J1/J4.
AID1346057Human lysine demethylase 6B (1.14.11.- Histone demethylases)2012Nature, Aug-16, Volume: 488, Issue:7411
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1249054Inhibition of KDM4E (unknown origin)2014MedChemComm, Dec-01, Volume: 5, Issue:12
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
AID1272797Intrinsic clearance in human liver microsomes at 1 uM up to 30 mins by LC/MS/MS analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.
AID1272798Half life in human liver microsomes at 1 uM by LC/MS/MS analysis2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.
AID1810145Inhibition of recombinant human MINA53 expressed in Escherichia coli BL21 (DE3) using RPL27A G31RGNAGGLHHHRINFDKYHP49 as substrate at 100 uM preincubated for 15 mins followed by substrate addition and measured after 30 to 60 mins by RapidFire Mass spectro2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53.
AID1249063Membrane permeability of the compound at pH 5 by PAMPA2014MedChemComm, Dec-01, Volume: 5, Issue:12
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
AID1543452Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-incubated for 5 mins before 2OG as substrate and Fe2 as co-factor addition in presence of L-ascorbate and me2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Inhibition of a viral prolyl hydroxylase.
AID1423426Binding affinity to KDM5A ARID/PhD1 domain deletion mutant (1 to 588 residues) (unknown origin) by ITC assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
AID1423423Inhibition of KDM4A (1 to 350 residues) (unknown origin) using H3 ( 1 to 15 residues) K9me3 as substrate preincubated for 15 min followed by substrate addition measured after 15 mins by FDH-coupled demethylase assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
AID1272801Inhibition of CYP2C9 in human liver microsomes at 10 uM after 20 mins2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.
AID1249061Membrane permeability of the compound at pH 7.4 by PAMPA2014MedChemComm, Dec-01, Volume: 5, Issue:12
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
AID1810144Inhibition of recombinant human NO66 expressed in Escherichia coli BL21 (DE3) using RPL8 N205PVEHPFGGGNHQHIGKPST224 as substrate at 100 uM preincubated for 15 mins followed by substrate addition and measured after 30 to 60 mins by RapidFire Mass spectrome2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53.
AID1272800Inhibition of CYP2D6 in human liver microsomes at 10 uM after 20 mins2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.
AID1423425Inhibition of KDM6A (880 to 1401 residues) (unknown origin) using H3 ( 21 to 44 residues) K27me3 as substrate preincubated for 15 min followed by substrate addition measured after 15 mins by FDH-coupled demethylase assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
AID1249062Membrane permeability of the compound at pH 6.2 by PAMPA2014MedChemComm, Dec-01, Volume: 5, Issue:12
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
AID1272799Inhibition of CYP3A4 in human liver microsomes at 10 uM after 20 mins2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.
AID1272803Inhibition of CYP2C19 in human liver microsomes at 10 uM after 20 mins2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.
AID1423463Selectivity ratio of IC50 for KDM4A (1 to 350 residues) (unknown origin) to IC50 for KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
AID1272794Inhibition of JMJD3 (unknown origin) using biotinylated H3K27me3 peptide as substrate after 1 hr by AlphaLISA assay2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.
AID1272802Inhibition of CYP1A2 in human liver microsomes at 10 uM after 20 mins2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Design and discovery of new pyrimidine coupled nitrogen aromatic rings as chelating groups of JMJD3 inhibitors.
AID1249069Inhibition of KDM6B (unknown origin)2014MedChemComm, Dec-01, Volume: 5, Issue:12
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
AID1249065Inhibition of KDM3A (unknown origin)2014MedChemComm, Dec-01, Volume: 5, Issue:12
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
AID1423464Selectivity ratio of IC50 for KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin) to IC50 for KDM6A (880 to 1401 residues) (unknown origin)2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
AID1423424Inhibition of KDM5A ARID/PhD1 domain deletion mutant (1 to 739 residues) (unknown origin) using H3 ( 1 to 24 residues) K4me3 as substrate preincubated for 15 min followed by substrate addition measured after 15 mins by FDH-coupled demethylase assay2018Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23
Structure-Based Engineering of Irreversible Inhibitors against Histone Lysine Demethylase KDM5A.
AID1594436Inhibition of C-terminal FLAG-tagged human KDM6B expressed in expressed in Sf9 cells pre-incubated for 4 hrs before substrate addition and measured after 1 hr by AlphaScreen assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Identification of ortho-hydroxy anilide as a novel scaffold for lysine demethylase 5 inhibitors.
AID1801992Demethylase AlphaScreen Assay from Article 10.1038/nchembio.2087: \\Structural analysis of human KDM5B guides histone demethylase inhibitor development.\\2016Nature chemical biology, 07, Volume: 12, Issue:7
Structural analysis of human KDM5B guides histone demethylase inhibitor development.
AID1801989KDM5 TR-FRET Assay from Article 10.1038/nchembio.2085: \\An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.\\2016Nature chemical biology, 07, Volume: 12, Issue:7
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
AID1801991KDM TR-FRET Assay from Article 10.1038/nchembio.2085: \\An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.\\2016Nature chemical biology, 07, Volume: 12, Issue:7
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
AID1801990KDM4C Enzymatic Screening Assay from Article 10.1038/nchembio.2085: \\An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.\\2016Nature chemical biology, 07, Volume: 12, Issue:7
An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's13 (61.90)24.3611
2020's8 (38.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.45 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]